282 related articles for article (PubMed ID: 38399945)
1. Selected Milestones in Antiviral Drug Development.
De Clercq E
Viruses; 2024 Jan; 16(2):. PubMed ID: 38399945
[TBL] [Abstract][Full Text] [Related]
2. New anti-HIV agents and targets.
De Clercq E
Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
[TBL] [Abstract][Full Text] [Related]
3. Antiviral drugs in current clinical use.
De Clercq E
J Clin Virol; 2004 Jun; 30(2):115-33. PubMed ID: 15125867
[TBL] [Abstract][Full Text] [Related]
4. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
5. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
De Clercq E
Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005
[TBL] [Abstract][Full Text] [Related]
6. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
Gu SX; Xue P; Ju XL; Zhu YY
Bioorg Med Chem; 2016 Nov; 24(21):5007-5016. PubMed ID: 27658796
[TBL] [Abstract][Full Text] [Related]
7. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
8. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
De Clercq E
Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
10. Emerging antiviral drugs.
De Clercq E
Expert Opin Emerg Drugs; 2008 Sep; 13(3):393-416. PubMed ID: 18764719
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.
Das K; Arnold E
Curr Opin Virol; 2013 Apr; 3(2):111-8. PubMed ID: 23602471
[TBL] [Abstract][Full Text] [Related]
12. Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains.
Yu F; Li W; Wang L; Dai Y; Lu X; Wang Q; Xie L; Jiang S
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004408
[TBL] [Abstract][Full Text] [Related]
13. Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
Xu H
Mini Rev Med Chem; 2010 Jan; 10(1):62-72. PubMed ID: 20380641
[TBL] [Abstract][Full Text] [Related]
14. Current insights and molecular docking studies of HIV-1 reverse transcriptase inhibitors.
Singh AK; Kumar A; Arora S; Kumar R; Verma A; Khalilullah H; Jaremko M; Emwas AH; Kumar P
Chem Biol Drug Des; 2024 Jan; 103(1):e14372. PubMed ID: 37817296
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
Piliero PJ
J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S2-S12. PubMed ID: 15319664
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in the Design and Development of Non-nucleoside Reverse Transcriptase Inhibitor Scaffolds.
Shirvani P; Fassihi A; Saghaie L
ChemMedChem; 2019 Jan; 14(1):52-77. PubMed ID: 30417561
[TBL] [Abstract][Full Text] [Related]
17. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Farmaco; 1999; 54(1-2):26-45. PubMed ID: 10321027
[TBL] [Abstract][Full Text] [Related]
18. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy.
Balzarini J
Biochem Pharmacol; 1999 Jul; 58(1):1-27. PubMed ID: 10403515
[TBL] [Abstract][Full Text] [Related]
19. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
[TBL] [Abstract][Full Text] [Related]
20. In search of a treatment for HIV--current therapies and the role of non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Reynolds C; de Koning CB; Pelly SC; van Otterlo WA; Bode ML
Chem Soc Rev; 2012 Jul; 41(13):4657-70. PubMed ID: 22618809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
